Real-World Study Demonstrates Benefits with Adjuvant Nivolumab in Resected Stage IIIA Melanoma
Source: Oncology Nursing News, November 2022
A significant portion of patients with resected stage IIIA melanoma were alive and recurrence free at a median follow-up of over 20 months following treatment with adjuvant nivolumab (Opdivo), according to a real-world analysis presented at the 19th International Congress of the Society for Melanoma Research.
Patients treated with adjuvant nivolumab (n = 171) achieved a 12-month recurrence-free survival (RFS) rate of 97.1% (95% CI, 93.1%-98.8%) compared with 81.6% (95% CI, 65.2%-90.8%) for patients who underwent observation (n = 38).The RFS rates at 18 months were 91.4% (95% CI, 85.6%-94.9%) vs 78.6% (95% CI, 61.6%-88.7%), respectively. The median RFS was not reached in either arm.
Additionally, treatment with neoadjuvant nivolumab improved 12- and 18-month overall survival (OS) rates; 98.2% (95% CI, 94.6%-99.4%) and 94.2% (95% CI, 89.1%-96.9%) compared with 94.7% (95% CI, 80.6%-98.7%) and 91.8% (95% CI, 76.6%-97.3%) in the observation group, respectively. The median OS was 34.6 months and not reached, respectively.